Subscribe to our newsletter.
Copyright 2025 © All rights Reserved Goffin Molecular Technologies
X
- No products in the list
Rapidly identifies viral or bacterial respiratory infections
Enables smarter, targeted antibiotic decisions
Detects CRP and MxA with one test
Improves early diagnosis and patient outcomes
The EZER CRP/MxA Combo Rapid Test enables fast detection of respiratory infections and helps distinguish between viral and bacterial causes. Using a simple blood sample, the test qualitatively measures two crucial markers: CRP (C-reactive protein) and MxA (Myxovirus resistance protein A).
MxA increases rapidly in viral infections, while CRP rises during bacterial infections. Since their response patterns differ, combining these markers in one test allows clinicians to identify the infection type more accurately — even when symptoms overlap.
This dual-biomarker strategy reduces diagnostic uncertainty and improves treatment decisions, especially in urgent care and general practice. By helping avoid unnecessary antibiotic use, it also supports better antibiotic stewardship.
For accurate, fast, and efficient diagnosis of respiratory infections using CRP, the CRP/MxA Combo Rapid Test is an essential tool for modern clinical practice.
The EZER CRP/MxA Combo Rapid Test is a lateral flow chromatographic immunoassay intended for the qualitative detection of CRP (C-reactive protein) and Myxovirus resistance protein A (MxA) in human whole blood. It supports healthcare professionals in determining whether a patient’s infection is of viral or bacterial origin. Note: diagnosis should always include clinical assessment and not rely solely on test results. This product is for in vitro diagnostic use only.
Acute respiratory infections (ARIs) affect around 20% of the population each year, including conditions like the common cold, flu, bronchitis, pharyngitis, and sinus infections. Due to overlapping symptoms, it’s often difficult for clinicians to differentiate between viral and bacterial infections based on symptoms alone. This uncertainty can lead to unnecessary antibiotic prescriptions, contributing to antimicrobial resistance.
Myxovirus resistance protein A (MxA) is an interferon-induced GTPase that responds specifically to viral infections. In healthy individuals, MxA levels are typically below 15 ng/mL. When a viral infection occurs, MxA levels:
Increase rapidly within 1–2 hours
Maintain elevated presence for over 2 days (half-life ≈ 2.3 days)
These properties make MxA a strong and reliable biomarker for acute viral infection detection.
C-reactive protein (CRP) is a general inflammatory biomarker. Under healthy conditions, CRP levels are extremely low. During a bacterial infection, however:
Levels rise within 4–6 hours
Peak at around 36 hours
Are minimally affected by viral infections
This makes CRP a valuable marker for identifying bacterial causes of respiratory illness.
The CRP/MxA Combo Rapid Test allows for the simultaneous detection of both biomarkers, providing a dual-indicator approach to infection diagnosis. This enables:
Better identification of clinically significant ARIs
Fast differentiation between viral and bacterial infections
More accurate, timely clinical decisions
By using both CRP and MxA markers in one rapid test, healthcare providers can:
Improve diagnostic accuracy
Avoid unnecessary antibiotics
Detect infections early
Enhance overall patient care
Product Catalogus
For any missing information or if you require additional details, please do not hesitate to contact us.
Subscribe to our newsletter.